Journal
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
Volume 18, Issue -, Pages 367-375Publisher
CELL PRESS
DOI: 10.1016/j.omtm.2020.06.013
Keywords
-
Categories
Funding
- Shenzhen Science and Technology Innovation Commission [ZDSYS20190902092903237, KQJSCX20170728150303243, JCYJ20180305124812444, JCYJ20170817093928508]
Ask authors/readers for more resources
The coronavirus disease 2019 (COVID-19) is a new type of pneumonia caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. COVID-19 is affecting millions of patients, and the infected number keeps increasing. SARS-CoV-2 is highly infectious, has a long incubation period, and causes a relatively high death rate, resulting in severe health problems all over the world. Currently there is no effective proven drug for the treatment of COVID-19; therefore, development of effective therapeutic drugs to suppress SARS-CoV-2 infection is urgently needed. In this review, we first summarize the structure and genome features of SARS-CoV-2 and introduce its infection and replication process. Then, we review the clinical symptoms, diagnosis, and treatment options of COVID-19 patients. We further discuss the potential molecular targets and drug development strategies for treatment of the emerging COVID-19. Finally, we summarize clinical trials of some potential therapeutic drugs and the results of vaccine development. This review provides some insights for the treatment of COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available